SCHEMBL3374645

SCHEMBL3374645

O=C(O)c1c(Br)cccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
RORC P51449 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
FABP4 P15090 1/20 0.39
PRNP P04156 1/20 0.39
PLK1 P53350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504216 0.86 CA12 (0.46) TAS2R14LMNAGAAALDH1A1HPGD
SCHEMBL28107141 0.83 SMN1; SMN2 (0.44) TAS2R14SMN1; SMN2LMNAGAARORC
SCHEMBL23908702 0.82 ALDH1A1 (0.51) TAS2R14LMNAGAAALDH1A1HPGD
SCHEMBL570378 0.79 CA12 (0.52) LMNAALDH1A1HPGDMEN1KMT2A
SCHEMBL503596 0.78 CES2 (0.50) TAS2R14ALDH1A1HPGDRORC
SCHEMBL24277954 0.78 CA12 (0.61) TAS2R14ALDH1A1HPGDCA1CA2
SCHEMBL2964734 0.78 TAS2R14 (0.51) TAS2R14LMNAGAAALDH1A1HPGD
SCHEMBL5322102 0.78 PRNP (0.37) TAS2R14HPGDMAPTKMT2AL3MBTL1
SCHEMBL31189227 0.78 PRNP (0.37) TAS2R14HPGDMAPTKMT2AL3MBTL1
SCHEMBL1486789 0.77 LMNA (0.44) TAS2R14LMNAGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed
CN-106928113-B Cathepsin K inhibitors and uses thereof 广东东阳光药业有限公司 2020-07-07 CN disclosed
EP-3207008-B1 PROCESS FOR THE PREPARATION OF 5-BROMO-1,2,3-TRICHLOROBENZENE SYNGENTA PARTICIPATIONS AG (CH) 2018-07-25 EP disclosed
US-9975823-B2 Process for the preparation of 5-bromo-1,2,3-trichlorobenzene SYNGENTA PARTICIPATIONS AG (CH) 2018-05-22 US disclosed
US-20170267611-A1 PROCESS FOR THE PREPARATION OF 5-BROMO-1,2,3-TRICHLOROBENZENE SYNGENTA PARTICIPATIONS AG (CH) 2017-09-21 US disclosed
US-20170267611-A1 PROCESS FOR THE PREPARATION OF 5-BROMO-1,2,3-TRICHLOROBENZENE SYNGENTA PARTICIPATIONS AG (CH) 2017-09-21 US disclosed
WO-2016058897-A1 PROCESS FOR THE PREPARATION OF 5-BROMO-1,2,3-TRICHLOROBENZENE SYNGENTA PARTICIPATIONS AG (CH) 2016-04-21 WO disclosed
US-20120277279-A1 Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions GLAXO GROUP LIMITED 2012-11-01 US disclosed
US-8247377-B2 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions GLAXO GROUP LIMITED (GB) 2012-08-21 US disclosed
EP-2029549-B1 PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2010-11-10 EP disclosed
US-20100234441-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-09-16 US disclosed
EP-2029549-A2 PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS Glaxo Group Limited (GB) 2009-03-04 EP disclosed
WO-2007144327-A2 PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234441-A1 NOVEL COMPOUNDS LTB4R2, TSLP, LTB4R TAS2R14 2856/4885SMN1; SMN2 4171/4885LMNA 4013/4885
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B TAS2R14 1406/4885SMN1; SMN2 195/4885LMNA 686/4885
US-20170267611-A1 PROCESS FOR THE PREPARATION OF 5-BROMO-1,2,3-TRICHLOROBENZENE TERT, CYP1B1, KAT5 TAS2R14 2303/4885SMN1; SMN2 3465/4885LMNA 2515/4885
US-20120277279-A1 Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions NR3C1, SERPINA6, PTGS1 TAS2R14 4323/4885SMN1; SMN2 4794/4885LMNA 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.